Overview

* Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs

* Cash position improves to $35.4 mln, supported by public offering and ATM facility

* NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers

Outlook

* Cash runway expected to support operations into 3Q-2027

Result Drivers

* Research and development expenses were $5.8 million for the three months ended September 30, 2025, compared to $2.8 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$7.50

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nuvectis Pharma Inc ( NVCT ) is $18.50, about 65.6% above its November 3 closing price of $6.36

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)